Seegene Introduces CURECA™, the Future of Fully Automated PCR Testing Solutions

Seegene's Groundbreaking CURECA™: The Next Generation of PCR Solutions

Seegene Inc., a recognized leader in the molecular diagnostics industry, is embarking on an ambitious journey to redefine laboratory automation with the introduction of CURECA™, a fully automated solution designed for Polymerase Chain Reaction (PCR) testing. With the need for swift and accurate diagnostic solutions continuing to grow, CURECA™ aims to meet these demands by integrating advanced automation into laboratories, thereby improving efficiency and accuracy in medical diagnostics.

What is CURECA™?

CURECA™, an acronym for Continuous Unlimited Random access Expandable and Customizable full Automation, encompasses two primary components: the Customizable Pre-treatment System (CPS) and the Customizable and Expandable Full Automation (CEFA). This innovative design aims to address the intricacies of PCR testing, particularly by easing the demanding pre-treatment stage, which has historically required significant manual intervention.

The CPS is responsible for sample loading and pre-treatment processes, while the CEFA component automates the steps necessary for nucleic acid extraction and gene amplification.

Enhancing Automation in PCR Testing

The pre-treatment phase of molecular diagnostics is vital but complex, dealing with various specimen types including stool, urine, blood, and sputum. Traditionally, this process relies on trained technicians to manage manual tasks including sample sorting and processing. Seegene's CURECA™ looks to streamline these operations through its CPS, which automates key functions such as sample sorting, centrifugation, vortexing, and heat treatment.

By reducing the manual workload on laboratory professionals, CURECA™ not only frees their time for more critical functions but also diminishes human error—ultimately fostering a more reliable diagnostic process. Furthermore, CPS has the potential to be used independently in other laboratory testing environments beyond PCR, showcasing its versatility in clinical diagnostics.

A Vision for the Future

The flexibility built into CURECA™ allows laboratories to adapt the system according to their specific operational needs. This adaptability ensures that laboratories can maintain high productivity—operating around the clock, seven days a week—and can handle increased throughput for PCR testing without compromising on quality or accuracy.

At the forthcoming European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025), Seegene will unveil a conceptual video that illustrates the envisioned workflow of this revolutionary system. Attendees will witness a simulation from sample loading to result analysis, demonstrating the potential of CURECA™ to reshape laboratory environments.

Commitment to Global Health Initiatives

Seegene's founder and CEO, Dr. Jong-Yoon Chun, underscores the importance of this initiative, stating, "Until now, there has been no system capable of fully automating pre-treatment processing for all specimen types, which has prevented true automation in MDx." He expressed that CURECA™ is a crucial step towards fulfilling Seegene's aspiration to create a world free from diseases by improving access to reliable diagnostic testing.

With an eye on public health, CURECA™ represents a pivotal advancement in molecular diagnostics, particularly in managing diseases and improving patient outcomes. Furthermore, as part of its broader mission, Seegene has launched a technology-sharing initiative. This aims to disseminate their cutting-edge diagnostic tools and data analysis technologies across global markets, empowering local entities to develop tailored diagnostic tests suited to their respective public health needs.

Looking Ahead

In addition to CURECA™, Seegene is set to showcase its range of syndromic real-time PCR assays at ESCMID Global 2025. This portfolio will include diagnostic solutions that respond to the growing challenges posed by antimicrobial resistance. With its innovative approach, Seegene sets out to redefine molecular diagnostics, promising not just to meet current needs but to anticipate future global health challenges.

With over two decades of experience in the field, particularly highlighted during the COVID-19 pandemic, Seegene is poised at the forefront of the diagnostic industry. CURECA™ is not just a product; it embodies the future of automated testing and the pursuit of improved health outcomes worldwide.

For more updates on CURECA™ and other innovations from Seegene, follow them on their official channels and stay tuned for live demonstrations at major upcoming medical conferences.